Type I interferon in systemic lupus erythematosus and other autoimmune diseases.
By Jacques Banchereau, V. Pascual. Immunity, 2006
995 citations recorded by the source corpus.
Subfields: Immunology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/145c682734aadb906aef1e2aa50510f335ee6412
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Type I interferons in host defense. (2006, neutral): “…into the well-established framework of IFN function that is discussed in the accompanying reviews (Honda et al., 2006; van Boxel-Dezaire et al., 2006; Banchereau and Pascual, 2006) and other papers (Honda et al., 2005b; Garcia-Sastre and Biron, 2006; Levy et al., 2003; Stark et al., 1998).”
- Netting neutrophils induce endothelial damage, infiltrate tissues and expose immunostimulatory molecules in systemic lupus erythematosus (2011, background): “This could promote chronic activation of the immune system and perpetuation of type I IFN synthesis characteristic of this disease (52).”
- Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development (2008, background): “Conversely, persistent activation of PDCs causes elevated IFN levels in autoimmune diseases such as lupus and psoriasis (Banchereau and Pascual, 2006).”
- Neutrophil Extracellular Traps and Its Implications in Inflammation: An Overview (2017, background): “Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3.”
- TAM receptors are pleiotropic inhibitors of the innate immune response. (2007, background): “…stimulation of DC maturation generated by elevated levels of type I IFNs and other proinflammatory cytokines, for example, is associated with the development of autoimmune diseases such as systemic lupus erythematosus (SLE), Sjögren’s syndrome, and psoriasis (Banchereau and Pascual, 2006).”